Patents by Inventor Adrian Thrasher

Adrian Thrasher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Optimised Coding Sequence and Promoter
    Publication number: 20210000978
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Application
    Filed: June 10, 2020
    Publication date: January 7, 2021
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
  • Optimised coding sequence and promoter
    Patent number: 10709796
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 14, 2020
    Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
  • Method for treating adenosine deaminase severe combined imunodeficiency
    Patent number: 10583180
    Abstract: The present invention relates to the prevention and/or treatment of ADA-SCID, in a patient.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: March 10, 2020
    Assignees: UCL Business LTD, The Regents of the University of California
    Inventors: Adrian Thrasher, Donald Kohn, Bobby Gaspar
  • Treatment of lysosomal storage diseases
    Patent number: 10576168
    Abstract: The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: March 3, 2020
    Assignee: UCL Business LTD
    Inventors: Bobby Gaspar, Adrian Thrasher, Michael Antoniou, Claudia Montiel-Equihua
  • Optimised Coding Sequence and Promoter
    Publication number: 20180008726
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Application
    Filed: July 17, 2017
    Publication date: January 11, 2018
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
  • Optimised coding sequence and promoter
    Patent number: 9764045
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: September 19, 2017
    Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John Mcvey, John Gray, Andrew Davidoff
  • TREATMENT
    Publication number: 20170173124
    Abstract: The present invention relates to the prevention and/or treatment of ADA-SCID, in a patient.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 22, 2017
    Inventors: Adrian THRASHER, Donald KOHN, Bobby GASPAR
  • TREATMENT
    Publication number: 20170173184
    Abstract: The present invention relates to the prevention and/or treatment of lysosomal storage diseases in a patient.
    Type: Application
    Filed: December 16, 2016
    Publication date: June 22, 2017
    Inventors: Bobby GASPAR, Adrian THRASHER, Michael ANTONIOU, Claudia MONTIEL-EQUIHUA
  • Optimised coding sequence and promoter
    Patent number: 9393323
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: July 19, 2016
    Assignees: UCL BUSINESS PLC, THROMBOSIS RESEARCH INSTITUTE, ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff
  • OPTIMISED CODING SEQUENCE AND PROMOTER
    Publication number: 20150273082
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocyte biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 1, 2015
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John Mcvey, John Gray, Andrew Davidoff
  • OPTIMISED CODING SEQUENCE AND PROMOTER
    Publication number: 20130024960
    Abstract: An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes are alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.
    Type: Application
    Filed: July 8, 2010
    Publication date: January 24, 2013
    Applicants: UCL BUSINESS PLC, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THROMBOSIS RESEARCH INSTITUTE
    Inventors: Amit Nathwani, Natalie Ward, Adrian Thrasher, Edward Tuddenham, John McVey, John Gray, Andrew Davidoff